Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Creatinolfosfate, also known as Creatinol-O-Phosphate or COP, is a cardioprotective drug and a structural analog of creatine. It functions in energy metabolism within muscle tissues by acting as a phosphagen, donating a phosphate group to ADP to regenerate ATP, which is crucial for muscle contraction. It also acts as an intracellular buffer, helping to prolong anaerobic glycolysis and prevent a significant drop in pH during intense muscle activity. Additionally, it exhibits anti-ischemic and anti-arrhythmic properties, maintaining ATP levels during ischemia, stabilizing cellular membranes, protecting cardiac cells from ischemic damage, and improving post-ischemic contractile function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Creatinolfosfate.